Cargando…
The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidenc...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341180/ https://www.ncbi.nlm.nih.gov/pubmed/35902200 http://dx.doi.org/10.1136/bmjopen-2021-060701 |
_version_ | 1784760557817036800 |
---|---|
author | Smith, Justine R Farrall, Alexandra L Davis, Janet L de Boer, Joke H Hall, Anthony J Mochizuki, Manabu Sen, H Nida Takase, Hiroshi ten Dam-van Loon, Ninette H Touitou, Valérie Vasconcelos-Santos, Daniel V Wilson, David J Yeh, Steven Radford, Mark H B |
author_facet | Smith, Justine R Farrall, Alexandra L Davis, Janet L de Boer, Joke H Hall, Anthony J Mochizuki, Manabu Sen, H Nida Takase, Hiroshi ten Dam-van Loon, Ninette H Touitou, Valérie Vasconcelos-Santos, Daniel V Wilson, David J Yeh, Steven Radford, Mark H B |
author_sort | Smith, Justine R |
collection | PubMed |
description | INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. METHODS AND ANALYSIS: The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). ETHICS AND DISSEMINATION: The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials. |
format | Online Article Text |
id | pubmed-9341180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93411802022-08-17 The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper Smith, Justine R Farrall, Alexandra L Davis, Janet L de Boer, Joke H Hall, Anthony J Mochizuki, Manabu Sen, H Nida Takase, Hiroshi ten Dam-van Loon, Ninette H Touitou, Valérie Vasconcelos-Santos, Daniel V Wilson, David J Yeh, Steven Radford, Mark H B BMJ Open Ophthalmology INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. METHODS AND ANALYSIS: The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). ETHICS AND DISSEMINATION: The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials. BMJ Publishing Group 2022-07-28 /pmc/articles/PMC9341180/ /pubmed/35902200 http://dx.doi.org/10.1136/bmjopen-2021-060701 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Ophthalmology Smith, Justine R Farrall, Alexandra L Davis, Janet L de Boer, Joke H Hall, Anthony J Mochizuki, Manabu Sen, H Nida Takase, Hiroshi ten Dam-van Loon, Ninette H Touitou, Valérie Vasconcelos-Santos, Daniel V Wilson, David J Yeh, Steven Radford, Mark H B The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title | The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title_full | The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title_fullStr | The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title_full_unstemmed | The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title_short | The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper |
title_sort | international vitreoretinal b-cell lymphoma registry: a protocol paper |
topic | Ophthalmology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341180/ https://www.ncbi.nlm.nih.gov/pubmed/35902200 http://dx.doi.org/10.1136/bmjopen-2021-060701 |
work_keys_str_mv | AT smithjustiner theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT farrallalexandral theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT davisjanetl theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT deboerjokeh theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT hallanthonyj theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT mochizukimanabu theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT senhnida theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT takasehiroshi theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT tendamvanloonninetteh theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT touitouvalerie theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT vasconcelossantosdanielv theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT wilsondavidj theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT yehsteven theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT radfordmarkhb theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT smithjustiner internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT farrallalexandral internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT davisjanetl internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT deboerjokeh internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT hallanthonyj internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT mochizukimanabu internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT senhnida internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT takasehiroshi internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT tendamvanloonninetteh internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT touitouvalerie internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT vasconcelossantosdanielv internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT wilsondavidj internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT yehsteven internationalvitreoretinalbcelllymphomaregistryaprotocolpaper AT radfordmarkhb internationalvitreoretinalbcelllymphomaregistryaprotocolpaper |